Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...

The ranibizumab injection could be administered in a convenient schedule twice per year for the treatment of diabetic macular ...

Hyperlipidemia has been linked to the presence of retinal hard exudates in patients with retinopathy and evidence ... retinal neuroglial abnormalities in diabetic rats. [21] However, further ...

The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...

Three experts discuss the increased mortality risk for patients with diabetic retinopathy, available screening tools, and ...

The new indication adds to the 2021 approval of Susvimo (ranibizumab) for 'wet' or neovascular age-related macular ...

Data from various retinal clinical trials suggest that there is a difference in efficacy in anti-VEGF therapies for patients ...

Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME) With as few as two treatments per year, Susvimo ...

There are around 537 million suffering with diabetes globally. Out of this, around 227 million people live in the Asia Pacific region. What is concerning is the fact that more than half of these ...